BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VERT-002 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VERT-002\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06669117-2792@assetmemo.bio
DTSTAMP:20261121T004529Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:VERT-002: Phase 1/2 readout est. (NCT06669117)
DESCRIPTION:VERT-002\, phase 1/2.\nStudy: FIH Trial of VERT-002 in Patients
  With Locally Advanced or Metastatic Solid Tumors With MET Alterations\nEs
 timated primary completion: 21 October 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/vert-002#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06669117
URL:https://assetmemo.bio/drug/vert-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
